Try our mobile app

Published: 2021-10-28 16:22:54 ET
<<<  go to MTLS company page
6-K 1 d205192d6k.htm FORM 6-K Form 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2021

Commission File Number: 001-36515

 

 

Materialise NV

 

 

Technologielaan 15

3001 Leuven

Belgium

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒            Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

This Form 6-K is incorporated by reference into the registrant’s Registration Statement on Form F-3 (File No. 333-213649).

 

 

 


Third Quarter 2021 Financial Results

Except as otherwise required by the context, references to “Materialise,” “Company,” “we,” “us” and “our” are to Materialise NV and its subsidiaries.

Third Quarter 2021 Results

Total revenue for the third quarter of 2021 increased 28.0% to 52,195 kEUR from 40,785 kEUR for the third quarter of 2020.

Revenue from our Materialise Software segment increased 10.4% to 10,468 kEUR for the third quarter of 2021 from 9,478 kEUR for the same quarter last year.

Revenue from our Materialise Medical segment increased 10.2% to 18,910 kEUR for the third quarter of 2021 compared to 17,161 kEUR for the same period in 2020.

Revenue from our Materialise Manufacturing segment increased 61.2% to 22,817 kEUR from 14,154 kEUR for the third quarter of 2020.

Gross profit was 31,076 kEUR, an increase of 33.4% compared to 23,303 kEUR for the same period last year, while the gross profit margin increased to 59.5% of total revenue compared to 57.1% for the third quarter of 2020.

Research and development (“R&D”), sales and marketing (“S&M”) and general and administrative (“G&A”) expenses increased, in the aggregate, 11.3% to 26,900 kEUR for the third quarter of 2021 from 24,176 kEUR for the third quarter of 2020.

Net other operating income was 355 kEUR compared to 1,157 kEUR for the third quarter of 2020. Operating result increased to 4,529 kEUR from 284 kEUR for the third quarter of 2020. Net financial result was 4,204 kEUR compared to (1,331) kEUR for the third quarter of 2020. The third quarter of 2021 contained income tax expenses of (80) kEUR, compared to 764 kEUR in the third quarter of 2020.

As a result of the above, our net result for the third quarter of 2021 increased 8,934 kEUR to a net profit of 8,652 kEUR, compared to a net loss of (282) kEUR for the same period in 2020. Total comprehensive income for the third quarter of 2021, which includes exchange differences on translation of foreign operations, was 8,267 kEUR compared to (1,659) kEUR for the 2020 period.

Adjusted EBITDA increased 62% to 9,739 kEUR from 6,023 kEUR in the previous period. The Adjusted EBITDA margin (Adjusted EBITDA divided by total revenue) for the third quarter of 2021 increased to 18.7% from 14.8% for the third quarter of 2020.

Segment EBITDA from our Materialise Software segment increased 19.1% to 3,708 kEUR from 3,114 kEUR while the segment EBITDA margin (segment EBITDA divided by segement revenue) increased to 35.4% compared to 32.9% in the prior-year period.

Segment EBITDA from our Materialise Medical segment decreased to 5,251 kEUR from 5,476 kEUR while the segment EBITDA margin was 27.8% compared to 31.9% for the third quarter of 2020.


Segment EBITDA from our Materialise Manufacturing segment increased to 3,546 kEUR from a loss of (321) kEUR while the segment EBITDA margin increased to 15.5% compared to (2.3)% in the third quarter of 2020.

At September 30, 2021, we had cash and cash equivalents of 194,946 kEUR compared to 111,538 kEUR at December 31, 2020. Gross debt amounted to 102,180 kEUR, compared to 115,110 kEUR at December 31, 2020. As a result, our net cash position (cash and cash equivalents less gross debt) was 92,766 kEUR at September 30, 2021, an improvement of 96,338 kEUR compared to December 31, 2020.

Cash flow from operating activities for the first three quarters of 2021 was 17,490 kEUR compared to 14,752 kEUR for the same period in 2020. Total capital expenditures for the third quarter of 2021 amounted to 3,252 kEUR.

Net shareholders’ equity at September 30, 2021 was 228,474 kEUR compared to 133,104 kEUR at December 31, 2020. In July 2021, we issued 600,000 new shares following the exercise of the underwriters’ option to purchase additional shares, in connection with the public offering of 4,000,000 shares issued in June 2021.

Non-IFRS Measures

Materialise uses EBITDA and Adjusted EBITDA as supplemental financial measures of its financial performance. EBITDA is calculated as net profit plus income taxes, financial expenses (less financial income), shares of profit or loss in a joint venture and depreciation and amortization. Adjusted EBITDA is determined by adding share-based compensation expenses, acquisition-related expenses of business combinations, impairments and revaluation of fair value due to business combinations to EBITDA. Management believes these non-IFRS measures to be important measures as they exclude the effects of items which primarily reflect the impact of long-term investment and financing decisions, rather than the performance of the company’s day-to-day operations. As compared to net profit, these measures are limited in that they do not reflect the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in the company’s business, or the charges associated with impairments. Management evaluates such items through other financial measures such as capital expenditures and cash flow provided by operating activities. The company believes that these measurements are useful to measure a company’s ability to grow or as a valuation measurement. The company’s calculation of EBITDA and Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. EBITDA and Adjusted EBITDA should not be considered as alternatives to net profit or any other performance measure derived in accordance with IFRS. The company’s presentation of EBITDA and Adjusted EBITDA should not be construed to imply that its future results will be unaffected by unusual or non-recurring items.

Exchange Rate

This document contains translations of certain euro amounts into U.S. dollars at specified rates solely for the convenience of readers. Unless otherwise noted, all translations from euros to U.S. dollars in this document were made at a rate of EUR 1.00 to USD 1.1579, the reference rate of the European Central Bank on September 30, 2021.

About Materialise

Materialise incorporates 30 years of 3D printing experience into a range of software solutions and 3D printing services, which form the backbone of the 3D printing industry. Materialise’s open and flexible solutions enable players in a wide variety of industries, including healthcare, automotive, aerospace, art and


design, and consumer goods, to build innovative 3D printing applications that aim to make the world a better and healthier place. Headquartered in Belgium, with branches worldwide, Materialise combines one of the largest groups of software developers in the industry with one of the largest 3D printing facilities in the world. For additional information, please visit: www.materialise.com.


Consolidated income statements (Unaudited)

 

     for the three months ended     for the nine months ended  
     September 30,     September 30,  
In 000€    2021     2021     2020 (*)     2021     2020  
     U.S.$                  

Revenue

     60,437       52,195       40,785       148,461       125,148  

Cost of Sales

     (24,454     (21,119     (17,483     (64,378     (57,310

Gross Profit

     35,983       31,076       23,303       84,084       67,838  

Gross profit as % of revenue

     59.5     59.5     57.1     56.6     54.2

Research and development expenses

     (7,644     (6,602     (5,861     (19,982     (18,434

Sales and marketing expenses

     (14,373     (12,413     (11,015     (35,730     (33,700

General and administrative expenses

     (9,130     (7,885     (7,300     (23,449     (21,100

Net other operating income (expenses)

     411       355       1,157       2,318       2,733  

Operating (loss) profit

     5,247       4,529       284       7,239       (2,663

Financial expenses

     2,703       2,334       (2,462     (3,182     (4,923

Financial income

     2,164       1,869       1,132       4,426       1,976  

Share in loss of joint venture

     —         —         —         —         (39

(Loss) profit before taxes

     10,114       8,732       (1,046     8,483       (5,649

Income Taxes

     (93     (80     764       (55     497  

Net (loss) profit for the period

     10,021       8,652       (282     8,428       (5,152

Net (loss) profit attributable to:

     —            

The owners of the parent

     10,022       8,655       (246     8,432       (4,989

Non-controlling interest

     (3     (3     (36     (4     (163

Earning per share attributable to owners of the parent

          

Basic

     0.17       0.15       (0.01     0.15       (0.01

Diluted

     0.17       0.15       (0.01     0.15       (0.01

Weighted average basic shares outstanding

     58,731       58,731       53,194       55,935       53,194  

Weighted average diluted shares outstanding

     58,944       58,944       53,194       56,206       53,194  

 

(*)

The year 2020 has been restated to reflect the final accounting of the business combination with Engimplan.

    

Impact on the quarter operating result was 83 kEUR, no impact on year to date operating result.


Consolidated statements of comprehensive income (Unaudited)

 

     for the three months ended     for the nine months ended  
     September 30,     September 30,  
In 000€    2021     2021     2020 (*)     2021     2020  
     U.S.$                  

Net profit (loss) for the period

     10,021       8,652       (282     8,428       (5,152

Other comprehensive income

          

Recycling

          

Exchange difference on translation of foreign operations

     (446     (385     (1,377     1,590       (8,165

Non-recycling

          

Fair value adjustments through OCI—Equity instruments

     —         —         —         48       —    

Other comprehensive income (loss), net of taxes

     (446     (385     (1,377     1,638       (8,165

Total comprehensive income (loss) for the year, net of taxes

     9,572       8,267       (1,659     10,066       (13,317

Total comprehensive income (loss) attributable to:

          

The owners of the parent

     9,576       8,270       (1,490     10,069       (11,968

Non-controlling interests

     (3     (3     (169     (3     (1,349

 

(*)

The year 2020 has been restated to reflect the final accounting of the business combination with Engimplan.

  

Impact on the quarter operating result was 83 kEUR, no impact on year to date operating result.


Consolidated statement of financial position (Unaudited)                

 

     As of
September
30,
     As of
December
31,
 
In 000€    2021      2020  

Assets

     

Non-current assets

     

Goodwill

     20,531        20,342  

Intangible assets

     31,534        32,981  

Property, plant & equipment

     84,512        88,267  

Right-of-Use assets

     9,109        10,996  

Investments in joint ventures

     —          —    

Deferred tax assets

     249        201  

Other non-current assets

     13,868        14,139  

Total non-current assets

     159,803        166,926  

Current assets

     

Inventories

     11,812        10,043  

Trade receivables

     38,543        30,871  

Other current assets

     9,767        8,290  

Cash and cash equivalents

     194,946        111,538  

Total non-current assets

     255,068        160,741  

Total assets

     414,871        327,667  


     As of
September
30,
    As of
December
31,
 
In 000€    2021     2020  

Equity and liabilities

    

Equity

    

Share capital

     4,445       4,096  

Share premium

     226,750       141,274  

Consolidated reserves

     3,430       (4,469

Other comprehensive income

     (6,158     (7,797

Equity attributable to the owners of the parent

     228,467       133,104  

Non-controlling interest

     7       —    

Total equity

     228,474       133,104  

Non-current liabilities

    

Loans & borrowings

     75,760       90,502  

Lease liabilities

     5,445       7,086  

Deferred tax liabilities

     6,175       6,805  

Deferred income

     4,812       5,327  

Other non-current liabilities

     2,151       398  

Total non-current liabilities

     94,343       110,118  

Current liabilities

    

Loans & borrowings

     17,740       13,984  

Lease liabilities

     3,235       3,538  

Trade payables

     22,357       17,698  

Tax payables

     1,311       974  

Deferred income

     30,174       29,554  

Other current liabilities

     17,237       18,697  

Total current liabilities

     92,054       84,445  

Total equity and liabilities

     414,871       327,667  


Consolidated statement of cash flows (Unaudited)

 

     for the nine months ended
September 30,
 
In 000€    2021     2020  

Operating activities

    

Net (loss) profit for the period

     8,429       (5,153

Non-cash and operational adjustments

    

Depreciation of property plant & equipment

     11,460       11,266  

Amortization of intangible assets

     3,780       3,349  

Share-based payment expense

     (878     —    

Loss (gain) on disposal of property, plant & equipment

     43       (16

Movement in provisions

     7       —    

Movement reserve for bad debt

     154       36  

Financial income

     (4,426     (1,977

Financial expense

     3,182       4,922  

Impact of foreign currencies

     107       18  

Share in loss (gain) of a joint venture (equity method)

     —         39  

(Deferred) income taxes

     55       (496

Other non-current liabilities

     —      

Working capital adjustments

     (4,531     5,221  

Decrease (increase) in trade receivables and other receivables

     (7,553     6,765  

Decrease (increase) in inventories

     (1,770     2,757  

Increase (decrease) in trade payables and other payables

     4,792       (4,301

Income tax paid & Interest received

     108       (2,457

Net cash flow from operating activities

     17,490       14,752  


     for the nine months ended
September 30,
 
In 000€    2021     2020  

Investing activities

    

Purchase of property, plant & equipment

     (4,827     (8,196

Purchase of intangible assets

     (2,439     (5,783

Proceeds from the sale of property, plant & equipment & intangible assets (net)

     295       150  

(Convertible) Loan to third party

     1,239       (2,428

Investment in subsidiary, net of cash acquired

     (1,680     —    

Net cash flow used in investing activities

     (7,412     (16,257

Financing activities

    

Repayment of loans & borrowings

     (11,169     (8,909

Repayment of finance leases

     (2,841     (2,997

Capital increase

     85,787       140  

Interest paid

     (1,652     (1,626

Other financial income (expense)

     2,740       (1,034

Net cash flow from (used in) financing activities

     72,865       (14,426

Net increase of cash & cash equivalents

     82,943       (15,931

Cash & Cash equivalents at the beginning of the year

     111,538       128,897  

Exchange rate differences on cash & cash equivalents

     465       (2,275

Cash & cash equivalents at end of the year

     194,946       110,691  


 

Reconciliation of Net Profit (Loss) to EBITDA and Adjusted EBITDA (Unaudited)

 

     for the three months ended
September 30,
    for the nine months ended
September 30,
 
In 000€    2021     2020(*)     2021     2020  

Net profit (loss) for the period

     8,652       (282     8,428       (5,152

Income taxes

     80       (764     55       (497

Financial expenses

     (2,334     2,462       3,182       4,923  

Financial income

     (1,869     (1,131     (4,426     (1,976

Depreciation and amortization

     5,314       4,839       15,240       14,616  

Share in loss of joint venture

     —         —         —         39  

EBITDA

     9,843       5,123       22,480       11,952  

Share-based compensation expense (1)

     (104     900       (878     1,057  

Acquisition-related expenses business combinations (2)

     —         —         405       —    

Adjusted EBITDA

     9,739       6,023       22,007       13,009  

 

(1)

Share-based compensation expense represents the cost of equity-settled and share-based payments to employees.

(2)

Acquisition-related expenses of business combinations represent expenses incurred in connection with the acquisition of our option to buy Link3D.

(*)

The year 2020 has been restated to reflect the final accounting of the business combination with Engimplan. Impact on the quarter operating result was 83 kEUR, no impact on year to date operating result.


Segment P&L (Unaudited)

 

In 000€    Materialise
Software
    Materialise
Medical
    Materialise
Manufacturing
    Total
segments
    Unallocated
(1)(2)
    Consolidated  

For the three months ended September 30, 2021

            

Revenues

     10,468       18,910       22,817       52,196       (0     52,195  

Segment (adj) EBITDA

     3,708       5,251       3,546       12,506       (2,767     9,739  

Segment (adj) EBITDA %

     35.4     27.8     15.5     24.0       18.7

For the three months ended September 30, 2020

            

Revenues

     9,478       17,161       14,154       40,793       (8     40,785  

Segment (adj) EBITDA

     3,114       5,476       (321     8,269       (2,246     6,023  

Segment (adj) EBITDA %

     32.9     31.9     -2.3     20.3       14.8
In 000€    Materialise
Software
    Materialise
Medical
    Materialise
Manufacturing
    Total
segments
    Unallocated
(1)(2)
    Consolidated  

For the nine months ended September 30, 2021

            

Revenues

     30,719       52,686       65,199       148,604       (142     148,461  

Segment (adj) EBITDA

     10,266       14,313       5,252       29,831       (7,826     22,004  

Segment (adj) EBITDA %

     33.4     27.2     8.1     20.1       14.8

For the nine months ended September 30, 2020

            

Revenues

     28,839       44,541       51,746       125,126       21       125,147  

Segment (adj) EBITDA

     9,515       9,072       1,447       20,035       (7,026     13,008  

Segment (adj) EBITDA %

     33.0     20.4     2.8     16.0       10.4

 

(1)

Unallocated Revenues consists of occasional one-off sales in our core competencies not allocated to any of our segments.

(2)

Unallocated segment adjusted EBITDA consists of corporate research and development, corporate headquarter costs and corporate other operating income (expense), and the added share-based compensation expenses, acquisition related expenses of business combinations, impairments and fair value of business combinations that are included in Adjusted EBITDA.


Reconciliation of Net Profit (Loss) to Segment EBITDA (Unaudited)

 

     for the three months ended
September 30,
    for the nine months ended
September 30,
 
In 000€    2021     2020 (*)     2021     2020  

Net profit (loss) for the period

     8,652       (282     8,428       (5,152

Income taxes

     80       (764     55       (497

Financial cost

     (2,334     2,462       3,182       4,923  

Financial income

     (1,869     (1,131     (4,426     (1,976

Share in loss of joint venture

         —         39  

Operating (loss) profit

     4,529       285       7,239       (2,663

Depreciation and amortization

     5,314       4,839       15,240       14,616  

Corporate research and development

     710       666       2,191       2,034  

Corporate headquarter costs

     2,463       2,969       6,907       7,862  

Other operating income (expense)

     (511     (492     (1,745     (1,816

Segment EBITDA

     12,506       8,269       29,831       20,035  

 

(*)

The year 2020 has been restated to reflect the final accounting of the business combination with Engimplan. Impact on the quarter operating result was 83 kEUR, no impact on year to date operating result.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

MATERIALISE NV
By:   /s/ Wilfried Vancraen
Name:   Wilfried Vancraen
Title:   Chief Executive Officer

Date: October 28, 2021